Last reviewed · How we verify
NCT07249086
Cohort of Nursing Homes
trial in Health Status in 1,500 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Institute of Hematology & Blood Diseases Hospital, China |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,500 |
| Start date | 30 November 2023 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2030 |
| Sites | 1 location across China |
Conditions studied
- Health Status — all drugs for Health Status →
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Who can join
60 and older, any sex, with Health Status. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study was to establish cohorts of elderly people in hospital care and elderly people in home care.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07249086
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Health Status
Currently open trials in the same condition.
- NCT07383974 — The Impact of 12 Week Retention of Nutrients on Skin and the Perception of Physical Health Status · NA · recruiting
- NCT06410014 — Assessment of Overall Functioning in Patients With Complex Health Issues · recruiting
- NCT07313631 — Impact Evaluation of Access to Free Low-Cost Health Insurance in Nigeria's Taraba State · NA · active not recruiting
- NCT05009433 — HIIT vs MICT During Pregnancy and Health and Birth Outcomes in Mothers and Children · NA · recruiting
Other Institute of Hematology & Blood Diseases Hospital, China trials
Trials by the same sponsor.
- NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
- NCT07407010 — BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM · Phase 1 · not yet recruiting
- NCT07407140 — VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML · Phase 3 · not yet recruiting
- NCT07454226 — ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL · NA · not yet recruiting
- NCT07490288 — Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07249086 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Hematology & Blood Diseases Hospital, China
- Last refreshed: 25 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07249086.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing